1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


TABLE 3: 
Regional rCBF before and after treatment
rCBF (ml/min/100g)Before Treatment6 Months After TreatmentP Value*
Symptomatic patients (n = 10)
    Resting23.3 ± 5.126.8 ± 7.3.1849
    Acetazolamide27.1 ± 5.138.0 ± 12.4.0166
    ΔF†3.9 ± 2.711.2 ± 7.0.0367
Asymptomatic patients (n = 4)
    Resting28.8 ± 8.230.1 ± 6.4>.05
    Acetazolamide38.4 ± 7.647.4 ± 8.6.0679
    ΔF†9.7 ± 2.617.2 ± 6.9.0679
  • * Wilcoxon signed rank test.
  • † Acetazolamide rCBF − resting rCBF.